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Ghrelin, des-acyl ghrelin, and obestatin are derived from a common prohormone, preproghrelin by posttranslational processing,
originating from endocrine cells in the stomach. To examine the regulatory roles of these peptides, we applied the manometric
measurement of gastrointestinal motility in freely moving conscious rat or mouse model. Ghrelin exerts stimulatory eﬀects on the
motility of antrum and duodenum in both fed and fasted state of animals. Des-acyl ghrelin exerts inhibitory eﬀects on the motility
of antrum but not on the motility of duodenum in the fasted state of animals. Obestatin exerts inhibitory eﬀects on the motility of
antrum and duodenum in the fed state but not in the fasted state of animals. NPY Y2 and Y4 receptors in the brain may mediate
the action of ghrelin, CRF type 2 receptor in the brain may mediate the action of des-acyl ghrelin, whereas CRF type 1 and type 2
receptors in the brain may mediate the action of obestatin. Vagal aﬀerent pathways might be involved in the action of ghrelin, but
notinvolvedintheactionofdes-acylghrelin,whereasvagalaﬀerentpathwaysmightbepartiallyinvolvedintheactionofobestatin.
1.Introduction
Ghrelin, des-acyl ghrelin, and obestatin are derived from
a prohormone, preproghrelin by posttranslational process-
ing. Ghrelin was ﬁrst identiﬁed as endogenous ligand for
growth hormone secretagogue receptors (GHS-R) with O-
n-octanoyl acid modiﬁcation at serine 3 position [1]. Des-
acyl ghrelin, on the other hand, has the same amino
acid sequence with no O-n-octanoyl acid modiﬁcation
[1]. Obestatin was found by a bioinformatics approach to
be encoded by preproghrelin [2]. Obestatin was initially
reported to be endogenous ligand for orphan G protein-
coupled receptor GPR39 [2]; however recent studies have
found no speciﬁc binding of obestatin to various types of
GPR39-expressing cells [3–5]. Ghrelin is a potent stimulator
of food intake and gastrointestinal motility [6], while des-
acyl ghrelin exerts opposite eﬀects on food intake and
gastrointestinal motility [7]. The eﬀects of obestatin on food
intake and gastrointestinal motility have been controversial
[8–13].
Recently we developed conscious rat and mouse models
to measure physiological fed and fasted motor activities in
the gastrointestinal tracts [14–18]. By using these models we
succeeded to examine the eﬀects of ghrelin, des-acyl ghrelin,
and obestatin on gastroduodenal motility and involvement
of hypothalamic peptides mediating the action of these
peptides. In this review, we overview the diﬀerent eﬀects
of ghrelin, des-acyl ghrelin, and obestatin on the upper
gastrointestinal motility with special attention being paid to
brain-gut interactions.2 International Journal of Peptides
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Figure 1: Localization of ghrelin, des-acyl ghrelin and obestatin in the rat stomach. (a) Immunoﬂuorescence double staining for acyl
ghrelin- (red) and des-acyl ghrelin-positive (green) reaction in the antral mucosa of rat stomach. Acyl ghrelin-positive reaction and des-acyl
ghrelin-positive reaction are colocalized in closed-type cells (arrows), whereas des-acyl ghrelin-positive reaction is localized in open-type
cells (arrowheads). (b) Immunoﬂuorescence triple staining for des-acyl ghrelin (green), acyl ghrelin (red) and obestatin (blue) in the antral
mucosa of rat stomach. Three peptides are colocalized in the closed-type cells (arrows). Bars = 10μm.
2. Localizationof Ghrelin,Des-Acyl Ghrelin,
andObestatinintheRatS t o mac h
The localization of ghrelin in the stomach has been studied
in various animals by using the speciﬁc antibody for ghrelin
[19, 20]; however, the localization of des-acyl ghrelin in
the stomach has been scarcely examined. We developed
antibodies speciﬁc for ghrelin (antirat octanoyl ghrelin (1-
15) -cys-KLH serum) and for des-acyl ghrelin (antirat des-
octanoyl ghrelin (1-15) -cis-KLH serum) and successfully
detected the diﬀerent localization of ghrelin and des-acyl
ghrelin in the rat stomach [21].International Journal of Peptides 3
Both ghrelin- and des-acyl ghrelin-immunoreactive cells
were distributed in the oxyntic and antral mucosa of the rat
stomach,withhigherdensityintheantralmucosathanoxyn-
tic mucosa. Immunoﬂuorescence double staining showed
that ghrelin- and des-acyl ghrelin-positive reactions over-
lapped in closed-type round cells, whereas des-acyl ghrelin-
positive reaction was found in open-type cells in which
ghrelin was negative (Figure 1(a)). Ghrelin/des-acyl ghrelin-
positive closed-type cells contain obestatin (Figure 1(b));
on the other hand des-acyl ghrelin-positive open-type cells
contain somatostatin [21].
Thecharacteristicfeaturesofopen-typecellsthatcontain
des-acyl ghrelin and closed-type cells that contain ghrelin
indicate that they may respond diﬀerently to intraluminal
factors. It is highly possible that open-type cells may react
to luminal stimuli more than closed-type cells. Therefore
we investigated the eﬀects of diﬀerent intragastric pH levels
on the release of ghrelin and that of des-acyl ghrelin from
the ex vivo perfused rat stomach [21]. In a preliminary
study we measured the intragastric pH levels in the fasting
and fed states of rats and found that intragastric pH in
the fasting state was pH 4, whereas that in the fed state
was pH 2 [16]. Our results showed that the release of
ghrelin was not aﬀected by intragastric pH, whereas the
release of des-acyl ghrelin was increased at intragastric pH
2 compared to that at intragastric pH 4 [21]. This result
suggests that des-acyl ghrelin-containing cells may sense the
intragastric pH via their cytoplasmic processes and release
the peptide in accordance with the lower intragastric pH.
The fact that the release of des-acyl ghrelin is stimulated
by lower intragastric pH seems reasonable because des-acyl
ghrelin may act as a satiety signal [6, 7] in the fed state of
animals.
3. Manometric Measurement of
GastrointestinalMotilityin
C o n s c io usM ic ean dR at s
We developed freely moving conscious animal model to
measure the gastrointestinal motility in rats [15]a n dm i c e
[18]. This model permits the measurement of gastroin-
testinal motility in animals in the physiological fed and
fasted states by a manometric method [15, 18]. In the
fasted state, the cyclic changes of pressure waves were
detected in both antrum and duodenum, including the
quiescence period during which relatively low amplitude
contractions occur (phase I-like contractions), followed by
a grouping of strong contractions (phase III-like contrac-
tions). The frequencies of phase III-like contractions in
the fasted motility in the antrum and duodenum in mice
(6.0 ± 0.2/h and 6.0 ± 0.3/h, resp.) were signiﬁcantly
(P<. 05) higher than those in rats (5.3 ± 0.5/h, 5.6
± 0.8/h, resp.) [15, 18]. After food intake, such fasted
motor pattern was disrupted and replaced by a fed motor
pattern, which consisted of irregular contractions of high
frequency.
4. Ghrelinand GastroduodenalMotility
Intracerebroventricular (i.c.v.) and intravenous (i.v.) injec-
tion of ghrelin stimulated the % motor index (%MI)
in the antrum and induced the fasted motor activity in
the duodenum when given in the fed state of animals
[16, 18]( Figure 2(a)). I.c.v. and i.v. injection of ghrelin
increased the frequency of phase III-like contractions in
both antrum and duodenum when given in the fasted state
of animals [16]. The eﬀects of i.v. injection of ghrelin
on gastroduodenal motility were blocked by i.v. injection
of GHS-R antagonist but not by i.c.v. injection of GHS-
R antagonist [16]. Immunoneutralization of NPY in the
brain blocked the stimulatory eﬀects of ghrelin on the
gastroduodenal motility [16]( Figure 2(b)). These results
indicate that ghrelin released from the stomach may act on
the ghrelin receptor on vagal aﬀerent nerve terminals and
NPY neurons in the brain may mediate the action of ghrelin
on the gastroduodenal motility (Figures 2(c) and 2(d)).
Our previous study showed that immunoneutralization of
NPY in the brain completely blocked the phase III-like
contractions in the duodenum of normal rats, and Y2 and
Y4 receptor agonists induced the phase III-like contractions
in the duodenum when given in the fed state of animals [15].
Combinedtogether,innormalanimalsghrelinmaystimulate
gastroduodenal motility by activating the GHS-R on vagal
aﬀerent nerve terminals and aﬀect NPY neurons in the
hypothalamus, and Y2 and/or Y4 receptors in the brain may
mediatetheactionofghrelin(Figure 2(d),Table 1).Oncethe
brain mechanism is eliminated by truncal vagotomy, ghrelin
might be primarily involved in the regulation of fasted
molility through GHS-R on the stomach and duodenum
[16].
Human ghrelin has a structural resemblance to human
motilin, and human ghrelin receptors exhibit a 50% identity
with human motilin receptors [22]. Therefore the role
of ghrelin in the gastrointestinal motility is comparable
with that of motilin [23, 24]. Motilin originates from
the endocrine cells in the duodenum [23], while ghrelin
originates from the endocrine cells in the stomach [20];
both of them are involved in the regulation of phase III
contractions in the gastrointestinal tracts. Motilin induces
fasted motility in the stomach and duodenum when it is
given peripherally but not when given centrally [24, 25],
while ghrelin induces fasted motility in the duodenum when
it is given both peripherally and centrally [16]. Since it is
known that gastric acidiﬁcation modulates the action of
motilin [26], we examined the relationship between the
eﬀects of ghrelin on gastroduodenal motility and intragastric
pH. The results showed that within 30 minutes after feeding
low intragastric pH (pH 2.5 ± 0.2) inhibited the eﬀects
i.v. injected ghrelin on gastroduodenal motility, and that
this eﬀect was reversed by an increase of intragastric pH
(pH 5.4 ± 0.6) within 60 minutes after feeding, or by
pretreatment of famotidine (intragastric pH 6.0–6.7) [16].
These results suggest that the sensitivity of the GHS-R in the
gastrointestinal tract might be inhibited by low intragastric
pH.4 International Journal of Peptides
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Figure 2: Eﬀe c t so fg h r e l i no nt h eg a s t r o d u o d e n a lm o t i l i t y .( a )E ﬀects of i.v. injection of ghrelin on the fed motor activity of the antrum
and duodenum. I.v. injection of ghrelin induces the fasted pattern in the duodenum and increases the motor activity in the antrum. (b) I.c.v.
injection NPY antiserum completely blocks the eﬀect of i.v. injection of ghrelin. (c) The density of c-Fos-positive cells in the arcuate nucleus
(ARC) and NTS is increased by i.p. injection of ghrelin compared to saline-injected control. (d) Summary diagram of the eﬀects of ghrelin
on the gastroduodenal motility and brain mechanism mediating its action.
Table 1: Summary of the regulatory roles of ghrelin, des-acyl ghrelin and obestatin on the gastroduodenal motility.
ghrelin des-acyl ghrelin obestatin
Fasted state Fed state Fasted state Fed state Fasted state Fed state
Stomach ↑↑↓ —— ↓
Duodenum ↑↑ ——— ↓
Hypothalamic neuron NPY urocortin 2 CRF, urocortin 2
Brain receptor Y2, Y4 CRF type 2 CRF type 1, type 2
Vagal aﬀerent pathway + — +
5.Des-AcylGhrelinand
GastroduodenalMotility
Centralandperipheraladministrationofdes-acylghrelinhas
been shown to signiﬁcantly decrease food intake in food-
deprived mice and decrease gastric emptying [6]. Transgenic
mice with overexpression of the des-acyl ghrelin gene
exhibitedadecreaseinbodyweight,foodintake,andfatmass
weight accompanied by moderately decreased linear growth
compared with their nontransgenic littermates [6]. In rats,
des-acyl ghrelin injected intraperitoneally (i.p.) eﬀectively
decreased food intake in food-deprived rats and decreased
the dark-phase food intake in free-feeding rats but failed to
decrease the light-phase food intake in free-feeding rats [7].International Journal of Peptides 5
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Figure 3: Eﬀects of des-acyl ghrelin on the gastroduodenal motility. (a) Eﬀects of i.v. injection of des-acyl ghrelin on the fasted motor
activities of the antrum and duodenum. I.v. injection of des-acyl ghrelin decreases the frequency of phase III-like contractions in the antrum
but not in the duodenum. (b) The decreased frequency of phase III-like contractions induced by i.v. injection of des-acyl ghrelin is restored
tonormalinpretreatmentofi.c.v.injectionoftheselectiveCRFtype2receptorantagonistantisauvagine-30.(c)Thedensityofc-Fos-positive
cells in the PVN is increased by i.p. injection of des-acyl ghrelin compared to saline-injected control, whereas that in the NTS is not altered.
(d) Summary diagram of the eﬀects of des-acyl ghrelin on the gastroduodenal motility and brain mechanism mediating its action.
I.c.v. and i.v. injections of des-acyl ghrelin disrupted
fasted motility in the antrum but not in the duodenum
[7]( Figure 3(a)). The frequencies of fasted motility in the
antrum were decreased to 58.9% and 54.5% by des-acyl
ghrelin injcted i.c.v. and i.v., respectively, [7]. However i.c.v.
and i.v. injections of des-acyl ghrelin did not alter fed
motor activity in both the antrum and duodenum [7]. These
data indicate that the dominant role of exogenous des-acyl
ghrelin aﬀects fasted motility in the antrum but not in
the duodenum. The results showed that capsaicin treatment
did not alter the disruptive eﬀect of i.v. injection of des-
acyl ghrelin on fasted motility in the antrum [7]. These
results were consistent with electrophysiological studies,
which showed that peripheral administration of ghrelin
suppressed ﬁring of the vagalaﬀerentpathways,whereasdes-
acyl ghrelin had no eﬀect on vagal aﬀerent pathways [27].
Diﬀerence in the involvement of vagal aﬀerent pathways in
the action of ghrelin and des-acy ghrelin was conﬁrmed
by c-Fos expression in the NTS. I.p. injection of ghrelin
signiﬁcantly increased the density of c-Fos-positive cells
in the NTS (Figure 2(c)), while i.p. injection of des-acyl
ghrelin induced no change in the density of c-Fos-positive
cells in the NTS compared with vehicle-injected controls
[7]( Figure 3(c)). Taken together, these results suggest that
peripherally administered des-acyl ghrelin may cross the
blood-brain barrier (BBB) and act directly on the brain
receptor and disrupt the fasted motility in the antrum
(Figure 3(d)).
The centrally administered CRF type 2 receptor antag-
onist, but not the CRF type 1 receptor antagonist, blocked
the eﬀects of centrally and peripherally administered des-
acyl ghrelin on gastric motility [7]( Figure 3(b)). Between6 International Journal of Peptides
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Figure 4: Eﬀects of obestatin on the gastroduodenal motility. (a) Eﬀects of i.v. injection of obestatin on the fed motor activity of the antrum
andduodenum.I.v.injectionofobestatinprolongsthetimebetween the initiationofphaseIII-likecontractions andinjectionofobestatinin
the duodenum. (b) The elongation of the time between injection of obestatin and initiation of phase III-like contractions in the duodenum
induced by i.v. injection of obestatin is reversed by i.c.v. injection of selective CRF type 1 receptor antagonist NBI-27914 and also by selective
CRF type 2 receptor antagonist antisauvagine-30. (c) The density of c-Fos-positive cells in the PVN is increased by i.v. injection of obestatin
compared to saline-injected control. CRF-positive or urocortin 2-positive neurons are overlapped with c-Fos-positive neurons in the PVN.
(d) Summary diagram of the eﬀects of obestatin on the gastroduodenal motility and brain mechanism mediating its action.
two CRF receptor subtypes, CRF type 1 receptor is highly
involvedinanxiety-relatedbehaviorandCRFtype2receptor
isinvolvedinregulatingfoodintakeandperipheralfunctions
such as gastric acid secretion or gastric emptying. CRF is a
relatively selective ligand for CRF type 1 receptor, whereas
urocortin 2 is a ligand more selective for CRF type 2 receptor
[28, 29]. The density of c-Fos-positive cells in the PVN was
signiﬁcantly increased by i.p. injection of des-acyl ghrelin
compared to vehicle-injected controls [7]( Figure 3(c)).
These data suggest that peripherally administered des-acylInternational Journal of Peptides 7
ghrelinmayactivateneuronsinthePVNbycrossingtheBBB
and exert inhibitory eﬀects on the antral motility via CRF
type 2 receptor in the brain (Figure 3(d), Table 1).
6. ObestatinandGastroduodenalMotility
Zhang et al. ﬁrst reported that i.p. injection of obestatin
suppressed cumulative food intake, decreased body weight
gain, and inhibited gastric emptying and jejunal muscle
contraction in mice [2]. Since then, however, the inhibitory
eﬀectsofobestatinonfoodintakeandgastrointestinalmotil-
ity have remained controversial [8–13]. Most of the previous
studies which showed the negative eﬀects of obestatin on
the gastrointestinal motility have only measured the gastric
emptying or MMC cycle time as indices for motor activity.
In our recent study, for more precise analysis, motor activity
in both fed and fasted states was quantiﬁed by the %MI, and
we measured the time taken to the initiation of phase III-like
contractions in the antrum and duodenum of conscious rats
[14].
We showed that motor activity in the antrum and
duodenum was inhibited when obestatin was given i.v. to
conscious rats in the fed state but not when it was given in
the fasted state [14]. I.v. injection of obestatin decreased the
%MI of fed motility in the antrum and prolonged the time
before the return of fasted motility in the duodenum [14]
(Figure 4(a)). Such inhibitory actions were the opposite of
those obtained with ghrelin [16]. The results showed that
the inhibitory action of obestatin appeared 30–90 minutes
after i.v. injection [14], which is consistent with the timing
of the eﬀects of i.v. injection of ghrelin (∼30 minutes)
on gastroduodenal motility [16]. I.v. injection of obestatin
inducedasigniﬁcantincreaseinthenumberofc-Fos-positive
cells in the PVN compared to saline-injected controls
[14]( Figure 4(c)). Immunoﬂuorescence overlap staining
showed that the PVN neurons activated by i.v. injection
of obestatin contain CRF or urocortin 2 [14]( Figure 4(c)).
The involvement of CRF type 1 and type 2 receptors in
the action of obestatin on the gastroduodenal motility was
examined [14]. Results showed that the inhibitory actions
of i.v. injection of obestatin on the motor activities in the
antrum and duodenum were blocked by i.c.v. injection of
CRF type 1 and type 2 receptor antagonists, suggesting that
both types of CRF receptors in the brain may mediate the
action of peripherally injected obestatin on gastroduodenal
motility [14]( Figure 4(b)). The results showed that vagal
aﬀerent nerve blockade by capsaicin reverses the inhibitory
eﬀects of obestatin on duodenal motility but does not alter
the inhibitory eﬀects of obestatin on antral motility [14].
These results suggest that vagal aﬀerent pathways might be
involved partially, but not entirely, in the action of obestatin.
Involvement of vagal aﬀerent pathways was conﬁrmed by the
ﬁndingthatthenumberofc-Fos-positiveneuronsintheNTS
was increased by i.v. injection of obestatin [14]. In addition
to vagal aﬀerent pathways, it is possible that circulating
obestatin acts on brain targets directly by crossing the BBB,
because a previous study has shown that there is a rapid
inﬂux of i.v.-injected 125I-labeled obestatin from the blood
to the brain [30]. Therefore the lack of eﬀects of obestatin
on antral motility during capsaicin treatment might be
explained by direct action of peripherally injected obestatin
onbraintargetsbycrossingtheBBB,similartowhathasbeen
observed for des-acyl ghrelin. We further examined whether
obestatin canantagonizethestimulatory eﬀectsof ghrelin on
gastroduodenal motility [14]. We found that obestatin failed
to antagonize the ability of ghrelin either to stimulate the
%MI in the antrum or to accelerate the initiation of fasted
motility in the duodenum when administrated in the fed
state[14].Theseresultswereconsistentwithpreviousstudies
in which obestatin failed to antagonize the ability of ghrelin
to stimulate gastric emptying or to shorten the MMC cycle
time [8].
GPR39 was initially proposed as the receptor for
obestatin [2], and GPR39 expression has been detected in
peripheral organs such as the duodenum and kidney but
not in the pituitary or hypothalamus [4]. However recent
publications indicate that obestatin is unlikely to be the
endogenous ligand for GPR39 on the basis of a lack of
speciﬁc binding of obestatin to GPR39 receptor-expressing
cells [2, 4, 5, 31]. Nevertheless, although binding of obestatin
to the receptor GPR39 remains controversial, the functional
eﬀect of obestatin on gastrointestinal motility has been
clearly demonstrated in our study.
Our study indicates that obestatin inhibits gastroduo-
denal motility in the fed state but not in the fasted state
of conscious rats. In the brain, CRF- and urocortin 2-
containing neurons might be activated by i.v. injection of
obestatin, and at the level, CRF type1 and type2 receptors
might be involved in the inhibitory action of obestatin
on antral and duodenal motility (Figure 4(d), Table 1).
Vagal aﬀerent pathways might be involved partially, but not
entirely, in these actions of obestatin (Figure 4(d), Table 1).
7. Conclusion
Although ghrelin, des-acyl ghrelin, and obestatin are derived
from a common prohormone, originating from endocrine
cells in the stomach, their roles on the gastrointestinal
motility are quite diﬀerent each other. Ghrelin stimulates the
gastroduodenal motility in both fed and fasted states, des-
acyl ghrelin inhibits the stomach motility in the fasted state,
and obestatin inhibits the gastroduodenal motility in the fed
state of animals (Table 1). Diﬀerent hypothalamic peptides
are involved in these actions, NPY Y2 and Y4 receptors
may mediate the action of ghrelin, CRF type 2 receptor
may mediate the action of des-acyl ghrelin, and CRF type
1 and type 2 receptors may mediate the action of obestatin
(Table 1). The regulatory roles of ghrelin, des-acyl ghrelin,
and obestatin on the gastrointestinal motility might give us
the therapeutic strategies for the functional disorders of the
gastrointestinal tracts
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